At a glance
- Originator Merck & Co
- Class Analgesics; Antipyretics; Nootropics
- Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic M3 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 21 Jan 1997 No-Development-Reported for Alzheimer's disease in United Kingdom (Unknown route)